Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent
19 déc. 2024 17h33 HE
|
Mangoceuticals, Inc.
Dallas, TX, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness...
IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer
19 déc. 2024 08h05 HE
|
Imunon, Inc.
Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001 Vertical integration of major components assures a high-quality, commercially viable...
NeuroOne® Product Revenue Increases 77% to $3.5 Million in Fiscal 2024: Expects Product Revenue to Increase at Least 132% to at Least $8 Million in Fiscal 2025
17 déc. 2024 08h30 HE
|
NeuroOne Medical Technologies Corp
Company’s Exclusive Distribution Agreement with Zimmer Biomet included $3.0 Million Upfront Payment: Expected to Drive Revenue and Expand Margins Significantly EDEN PRAIRIE, Minn., Dec. 17, 2024 ...
At EuroEcho, Ebit (Esaote Group) presents the world premiere of ZEfiRO, the new “cloud-native” PACS for the SUITESTENSA platform, redefining its design philosophy
13 déc. 2024 07h25 HE
|
Esaote
BERLIN and GENOA, Italy, Dec. 13, 2024 (GLOBE NEWSWIRE) -- EBIT s.r.l., the Esaote Group company that leads the Information Technology sector in the Healthcare field, is presenting the world...
[Latest] Global Dry Eye Syndrome Treatment Market Size/Share Worth USD 12,281.4 Million by 2033 at a 7.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
11 déc. 2024 12h30 HE
|
Custom Market Insights
Austin, TX, USA, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Dry Eye Syndrome Treatment Market Size, Trends and Insights By Type (Evaporative...
[Latest] Global Epilepsy Treatment Devices Market Size/Share Worth USD 787.3 Million by 2033 at a 4.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
19 nov. 2024 11h30 HE
|
Custom Market Insights
Austin, TX, USA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Epilepsy Treatment Devices Market Size, Trends and Insights By Product Type...
Tremfya's Promising Debut Boosts Momentum for IL-23 Class in Ulcerative Colitis Treatment, According to Spherix Global Insights
15 nov. 2024 09h38 HE
|
Spherix Global Insights
EXTON, PA, Nov. 15, 2024 (GLOBE NEWSWIRE) -- In what has been a transformative year for ulcerative colitis (UC) treatment, the IL-23 class has solidified its role as a key therapeutic treatment...
Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)
07 nov. 2024 08h30 HE
|
Palisade Bio, Inc.
Carlsbad, CA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing...
Sermonix Surveys Find Vaginal/Sexual Health Symptoms Are Among Most Significant Issues Affecting Lives of ER+/HER2- Metastatic Breast Cancer Patients
02 nov. 2024 09h00 HE
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Nov. 02, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis
31 oct. 2024 08h30 HE
|
Palisade Bio, Inc.
Targeted, better-tolerated oral PDE4 inhibitors are an unmet need in inflammatory bowel disease (IBD) PALI-2108 demonstrates in ex vivo studies; targeted activation and reduced side effects,...